ATC code J
Source: Wikipedia, the free encyclopedia.
Pharmaceutical drug classification
ATC code J: Antiinfectives for systemic use |
---|
|
Human only |
|
ATCvet only |
|
Other ATC codes |
ATC code J Antiinfectives for systemic use is a section of the
Codes for
ATCvet codes) can be created by placing the letter Q in front of the human ATC code: for example, QJ.[5]
ATCvet codes without corresponding human ATC codes are cited with the leading Q in the following list.National issues of the ATC classification may include additional codes not present in this list, which follows the WHO version.
See also
- Immune sera, immunoglobulins and vaccines for veterinary use are in the ATCvet group QI.
References
- ^ "ATC (Anatomical Therapeutic Chemical Classification System) – Synopsis". National Institutes of Health. Retrieved 1 February 2020.
- ^ World Health Organization. "Anatomical Therapeutic Chemical (ATC) Classification". World Health Organization. Retrieved 3 January 2022.
- ^ "Structure and principles". WHO Collaborating Centre for Drug Statistics Methodology. 15 February 2018. Retrieved 3 January 2022.
- ^ "ATC/DDD Index 2022: code J". WHO Collaborating Centre for Drug Statistics Methodology.
- ^ "ATCvet Index 2022: code QJ". WHO Collaborating Centre for Drug Statistics Methodology.
|
| |||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
50S | ||||||||||||||||
EF-G |
| |||||||||||||||
|
|
| |||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Polypeptides |
| |||||||||||||||||||||||||||||||||||||||||||
Intracellular |
| |||||||||||||||||||||||||||||||||||||||||||
Other |
| |||||||||||||||||||||||||||||||||||||||||||
|
Antifolates (inhibit bacterial purine metabolism, thereby inhibiting DNA and RNA synthesis) |
| ||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Quinolones (inhibit bacterial topoisomerase and/or DNA gyrase, thereby inhibiting DNA replication) |
| ||||||||||||||||
Anaerobic DNA inhibitors |
| ||||||||||||||||
RNA synthesis |
| ||||||||||||||||
|
Other/ungrouped |
|
---|
|
| |||||||
---|---|---|---|---|---|---|---|---|
Polyene antimycotics (ergosterol binding) |
| |||||||
Squalene monooxygenase inhibitors |
| |||||||
Others |
|
inhibitors
Pyrimidine analogues/ thymidylate synthase inhibitors |
|
---|---|
Mitotic inhibitors |
|
Aminoacyl tRNA synthetase inhibitors |
|
- bromochlorosalicylanilide
- chlorophetanol
- chlorphenesin
- ciclopirox
- crystal violet
- dimazole
- ethylparaben
- haloprogin‡
- polynoxylin
- potassium iodide#
- salicylic acid
- selenium disulfide#
- sodium thiosulfate#
- sulbentine
- taurolidine
- ticlatone
- tolciclate
- tolnaftate
- tribromometacresol
- undecylenic acid
- Whitfield's ointment#
- citronella oil
- lemon grass
- lemon myrtle
- orange oil
- patchouli
- tea tree oil
- PCP: atovaquone
- dapsone
- pentamidine
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
| |||||||||
---|---|---|---|---|---|---|---|---|---|
Nucleic acid inhibitor |
| ||||||||
Protein synthesis inhibitor |
| ||||||||
Cell envelope antibiotic |
| ||||||||
Other/unknown | |||||||||
Combinations | |||||||||
|
Baltimore I |
| ||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Hepatitis B (VII) | |||||||||||||||||||||
Multiple/general |
| ||||||||||||||||||||
|
| ||
---|---|---|
NS5A inhibitors (–asvir) | ||
NS5B RNA polymerase inhibitors (–buvir) | ||
Combination drugs |
Interferon |
|
---|---|
3CL protease inhibitors (–trelvir) |
|
RNA pol inhibitors |
|
Multiple/Unknown/Other |
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
Capsid inhibitors | |||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Discovery and development ) |
| ||||||||||||
Integrase inhibitors (Integrase strand transfer inhibitors (INSTI)) | |||||||||||||
Maturation inhibitors | |||||||||||||
Discovery and development ) |
| ||||||||||||
Reverse-transcriptase inhibitors (RTIs) |
| ||||||||||||
Combined formulations |
| ||||||||||||
Pharmacokinetic boosters | |||||||||||||
Experimental agents |
| ||||||||||||
|